Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer

A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette–Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Med Oncol
Glavni autori: Liem, Esmee I. M. L., Baard, Joyce, Cauberg, Evelyne C. C., Bus, Mieke T. J., de Bruin, D. Martijn, Laguna Pes, M. Pilar, de la Rosette, Jean J. M. C. H., de Reijke, Theo M.
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2017
Teme:
Original Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581817/
https://ncbi.nlm.nih.gov/pubmed/28866819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-1033-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items